This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement
updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and …

Advances in our understanding of the ways in which the traditional cardiovascular risk factors,
including standard lipid (eg, total cholesterol, low-density lipoprotein cholesterol, and high-…

Cumulating evidence suggests that an intact glycocalyx protects the vessel wall, whereas
disruption of the glycocalyx upon atherogenic stimuli increases vascular vulnerability for …

Background Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density
lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on …

Recent advances in human genetics, together with a large body of epidemiologic, preclinical,
and clinical trial results, provide strong support for a causal association between …

The intestinal microbiota has been implicated in insulin resistance, although evidence
regarding causality in humans is scarce. We therefore studied the effect of lean donor (allogenic) …

Hyperglycemia is associated with increased susceptibility to atherothrombotic stimuli. The
glycocalyx, a layer of proteoglycans covering the endothelium, is involved in the protective …

Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein
convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma …

Objectives : This study was designed to assess the relationship of high-density-lipoprotein
cholesterol (HDL-C), HDL particle size, and apolipoprotein AI (apoA-I) with the occurrence of …

Objectives : The aim of this research was to estimate the efficacy and safety of current high-density
lipoprotein cholesterol (HDL-C)-increasing drugs. Background : Epidemiologic …